|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHPS |
Gene summary for DHPS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHPS | Gene ID | 1725 |
| Gene name | deoxyhypusine synthase | |
| Gene Alias | DHS | |
| Cytomap | 19p13.13 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | P49366 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1725 | DHPS | LZE4T | Human | Esophagus | ESCC | 1.35e-14 | 3.25e-01 | 0.0811 |
| 1725 | DHPS | LZE7T | Human | Esophagus | ESCC | 5.10e-17 | 6.30e-01 | 0.0667 |
| 1725 | DHPS | LZE8T | Human | Esophagus | ESCC | 1.84e-03 | 1.65e-01 | 0.067 |
| 1725 | DHPS | LZE20T | Human | Esophagus | ESCC | 6.08e-05 | 3.41e-01 | 0.0662 |
| 1725 | DHPS | LZE22T | Human | Esophagus | ESCC | 1.46e-06 | 3.58e-01 | 0.068 |
| 1725 | DHPS | LZE24T | Human | Esophagus | ESCC | 4.71e-25 | 7.70e-01 | 0.0596 |
| 1725 | DHPS | LZE6T | Human | Esophagus | ESCC | 2.98e-11 | 6.73e-01 | 0.0845 |
| 1725 | DHPS | P1T-E | Human | Esophagus | ESCC | 7.36e-15 | 8.12e-01 | 0.0875 |
| 1725 | DHPS | P2T-E | Human | Esophagus | ESCC | 6.46e-26 | 4.85e-01 | 0.1177 |
| 1725 | DHPS | P4T-E | Human | Esophagus | ESCC | 3.49e-33 | 9.13e-01 | 0.1323 |
| 1725 | DHPS | P5T-E | Human | Esophagus | ESCC | 5.13e-27 | 6.21e-01 | 0.1327 |
| 1725 | DHPS | P8T-E | Human | Esophagus | ESCC | 1.58e-25 | 5.18e-01 | 0.0889 |
| 1725 | DHPS | P9T-E | Human | Esophagus | ESCC | 3.11e-28 | 7.76e-01 | 0.1131 |
| 1725 | DHPS | P10T-E | Human | Esophagus | ESCC | 1.44e-57 | 1.05e+00 | 0.116 |
| 1725 | DHPS | P11T-E | Human | Esophagus | ESCC | 6.92e-15 | 7.33e-01 | 0.1426 |
| 1725 | DHPS | P12T-E | Human | Esophagus | ESCC | 5.25e-46 | 9.27e-01 | 0.1122 |
| 1725 | DHPS | P15T-E | Human | Esophagus | ESCC | 4.11e-30 | 5.62e-01 | 0.1149 |
| 1725 | DHPS | P16T-E | Human | Esophagus | ESCC | 5.59e-36 | 7.52e-01 | 0.1153 |
| 1725 | DHPS | P17T-E | Human | Esophagus | ESCC | 2.90e-20 | 7.82e-01 | 0.1278 |
| 1725 | DHPS | P19T-E | Human | Esophagus | ESCC | 1.14e-14 | 1.13e+00 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:00516046 | Liver | Cirrhotic | protein maturation | 121/4634 | 294/18723 | 3.54e-10 | 1.68e-08 | 121 |
| GO:00182051 | Liver | Cirrhotic | peptidyl-lysine modification | 134/4634 | 376/18723 | 1.29e-06 | 2.59e-05 | 134 |
| GO:0006595 | Liver | Cirrhotic | polyamine metabolic process | 12/4634 | 18/18723 | 2.07e-04 | 1.90e-03 | 12 |
| GO:0044106 | Liver | Cirrhotic | cellular amine metabolic process | 43/4634 | 113/18723 | 1.15e-03 | 7.83e-03 | 43 |
| GO:0006576 | Liver | Cirrhotic | cellular biogenic amine metabolic process | 38/4634 | 101/18723 | 2.72e-03 | 1.59e-02 | 38 |
| GO:0009308 | Liver | Cirrhotic | amine metabolic process | 43/4634 | 118/18723 | 3.03e-03 | 1.72e-02 | 43 |
| GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
| GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
| GO:00065951 | Liver | HCC | polyamine metabolic process | 14/7958 | 18/18723 | 2.57e-03 | 1.23e-02 | 14 |
| GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
| GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
| GO:00065954 | Oral cavity | OSCC | polyamine metabolic process | 13/7305 | 18/18723 | 4.45e-03 | 1.79e-02 | 13 |
| GO:005160416 | Oral cavity | LP | protein maturation | 122/4623 | 294/18723 | 1.37e-10 | 7.72e-09 | 122 |
| GO:001820513 | Oral cavity | LP | peptidyl-lysine modification | 136/4623 | 376/18723 | 3.64e-07 | 1.06e-05 | 136 |
| GO:000659512 | Oral cavity | LP | polyamine metabolic process | 13/4623 | 18/18723 | 2.94e-05 | 4.58e-04 | 13 |
| GO:005160419 | Skin | cSCC | protein maturation | 117/4864 | 294/18723 | 1.27e-07 | 2.93e-06 | 117 |
| GO:001820515 | Skin | cSCC | peptidyl-lysine modification | 137/4864 | 376/18723 | 4.09e-06 | 6.09e-05 | 137 |
| GO:000659513 | Skin | cSCC | polyamine metabolic process | 11/4864 | 18/18723 | 1.74e-03 | 1.06e-02 | 11 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHPS | SNV | Missense_Mutation | c.108N>G | p.Phe36Leu | p.F36L | P49366 | protein_coding | deleterious(0.02) | benign(0.124) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DHPS | SNV | Missense_Mutation | rs1050609 | c.254N>T | p.Ala85Val | p.A85V | P49366 | protein_coding | tolerated(0.53) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DHPS | SNV | Missense_Mutation | c.147N>G | p.Phe49Leu | p.F49L | P49366 | protein_coding | tolerated(0.28) | benign(0) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| DHPS | SNV | Missense_Mutation | rs777080975 | c.374N>G | p.Val125Gly | p.V125G | P49366 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| DHPS | insertion | In_Frame_Ins | novel | c.524_525insGCCTACTTACTCTTTCTTTTTTACGAGACAGGGTCTCATTCTGTT | p.Asn175delinsLysProThrTyrSerPhePhePheThrArgGlnGlyLeuIleLeuPhe | p.N175delinsKPTYSFFFTRQGLILF | P49366 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| DHPS | SNV | Missense_Mutation | novel | c.1066N>A | p.Ala356Thr | p.A356T | P49366 | protein_coding | deleterious(0) | possibly_damaging(0.454) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DHPS | SNV | Missense_Mutation | c.800N>G | p.Asn267Ser | p.N267S | P49366 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-FU-A3TQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| DHPS | SNV | Missense_Mutation | c.147C>G | p.Phe49Leu | p.F49L | P49366 | protein_coding | tolerated(0.28) | benign(0) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DHPS | SNV | Missense_Mutation | c.147N>A | p.Phe49Leu | p.F49L | P49366 | protein_coding | tolerated(0.28) | benign(0) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DHPS | SNV | Missense_Mutation | novel | c.277N>T | p.Pro93Ser | p.P93S | P49366 | protein_coding | tolerated(0.51) | benign(0.003) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1725 | DHPS | NA | DEOXYSPERGUALIN | 11964177 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |